Molecular Cancer is delighted to announce the new thematic series entitled 'mRNA therapies and mRNA vaccines in cancer.'
Click here to view this collection.
Click here to access all thematic series published to date in Molecular Cancer.
Christophe Nicot, Kansas University Medical Center, USA
Molecular Cancer is an open access, peer-reviewed journal interested in attracting high-quality original research and reviews that present or highlight significant advances in all areas of cancer and related biomedical science.
In this review, Sahebkar et al. summarize the current knowledge on the contribution of the NLRP3 inflammasome on potential cancer promotion and therapy.
Molecular Cancer is a top rated Springer Nature journal. Prof. Christophe Nicot and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.
Click here to see which articles published in Molecular Cancer have been shared the most in the past three months.
48 days to first decision for reviewed manuscripts only
12 days to first decision for all manuscripts
118 days from submission to acceptance
19 days from acceptance to publication
15.302 - 2-year Impact Factor
10.478 - 5-year Impact Factor
2.969 - Source Normalized Impact per Paper (SNIP)
4.581 - SCImago Journal Rank (SJR)
196 Altmetric mentions